Previous 10 | Next 10 |
Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders PR Newswire Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKB...
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023 PR Newswire CAMBRIDGE, Mass. , April 7, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose ...
2023-04-03 12:52:16 ET When searching for penny stocks to buy or watch, it’s important to focus on catalysts. Penny stocks , which are stocks priced under $5 per share, often attract small and new investors. However, investing in these stocks comes with inherent risks. So it ...
2023-04-03 08:55:12 ET Akebia Therapeutics ( NASDAQ: AKBA ) said that top-line results showed that dosing experimental anemia treatment vadadustat three times weekly met primary and secondary endpoints. In the open-label trial, hemodialysis patients were randomized to vada...
Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study PR Newswire Data demonstrated that vadadustat met the primary and secondary efficacy endpoints and was non-inferior to an ESA as a treatment for anemia due to chronic kidney diseas...
Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat PR Newswire CAMBRIDGE, Mass. , March 30, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the liv...
2023-03-24 10:55:06 ET Akebia Therapeutics ( NASDAQ: AKBA ) is down 5% Friday morning after filing a revised proxy statement for an April share holder meeting where a reverse stock split will be voted on. The split is necessary for the biotech to regain compliance with...
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting PR Newswire CAMBRIDGE, Mass. , March 24, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the liv...
2023-03-09 12:57:08 ET Akebia Therapeutics, Inc. (AKBA) Q4 2022 Earnings Conference Call March 09, 2023, 08:30 AM ET Company Participants Mercedes Carrasco - Investor Relations and Corporate Communications John Butler - President and Chief Executive Officer David...
2023-03-09 12:48:42 ET Gainers: Intuitive Machines ( LUNR ) +74% . Ocean Biomedical ( OCEA ) +72% . Holley ( HLLY ) +55% . Build-A-Bear Workshop ( BBW ) +23% . Avenue Therapeutics ( ATXI ) +21% . Digital Brands Group ( DBGI...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...